bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 2 from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas
Authors: Malouf Gabriel G. , Su Xiaoping , Zhang Jianping , Creighton Chad J. , Ho Thai H. , Lu Yue , Raynal Noël J.-M. , Karam Jose A. , Tamboli Pheroze , Allanick Frederick , Mouawad Roger , Spano Jean-Philippe , Khayat David , Wood Christopher G. , Jelinek Jaroslav , Tannir Nizar M.
Published: April 2023

List of 95 CpG located in promoter CG islands which are differentially methylated and expressed between C1 and C2 epi-clusters.
Supplemental Table 1 from A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Authors: Fouladi Maryam , Perentesis John P. , Wagner Lars M. , Vinks Alexander A. , Reid Joel M. , Ahern Charlotte , Thomas George , Mercer Carol A. , Krueger Darcy A. , Houghton Peter J. , Doyle L. Austin , Chen Helen , Weigel Brenda , Blaney Susan M.
Published: April 2023

Supplemental Table 1. IMC-A12 trough serum concentrations during cycle 1 and cycle 2
Supplemental Figure 3A and 3B from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Authors: Doñate Fernando , Raitano Arthur , Morrison Kendall , An Zili , Capo Linnette , Aviña Hector , Karki Sher , Morrison Karen , Yang Peng , Ou Jimmy , Moriya Ryuichi , Shostak Yuriy , Malik Faisal , Nadell Rossana , Liu Wendy , Satpayev Daulet , Atkinson John , Joseph Ingrid B.J. , Pereira Daniel S. , Challita-Eid Pia M. , Stover David R.
Published: April 2023

Supplemental Figure 3A. Mapping of AGS16-7.8 binding to different ENNP3 domains. Supplemental Figure 3B. Western blots for mapping recognition of epitopes in ENPP3 ECD fragments.
Sapplemental Table 1 from An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy
Authors: Noguchi Masanori , Matsumoto Kazumasa , Uemura Hirotsugu , Arai Gaku , Eto Masatoshi , Naito Seiji , Ohyama Chikara , Nasu Yasutomo , Tanaka Masatoshi , Moriya Fukuko , Suekane Shigetaka , Matsueda Satoko , Komatsu Nobukazu , Sasada Tetsuro , Yamada Akira , Kakuma Tatsuyuki , Itoh Kyogo
Published: April 2023

Supplemental table 1. Peptide candidates for personalized peptide vaccination
Supplementary Table 1 from Cisplatin-Induced Renal Injury Is Independently Mediated by OCT2 and p53
Authors: Sprowl Jason A. , Lancaster Cynthia S. , Pabla Navjotsingh , Hermann Edwin , Kosloske Ashley M. , Gibson Alice A. , Li Lie , Zeeh Dorothea , Schlatter Eberhard , Janke Laura J. , Ciarimboli Giuliano , Sparreboom Alex
Published: April 2023

PDF file - 70K, Changes in gene expression of 25 genes associated with the p53 signaling pathway in kidneys isolated from wildtype and Oct1/2(-/-) FVB mice exposed to cisplatin (15 mg/kg cisplatin; i.p.).
Supplementary Figure Legends from Cisplatin-Induced Renal Injury Is Independently Mediated by OCT2 and p53
Authors: Sprowl Jason A. , Lancaster Cynthia S. , Pabla Navjotsingh , Hermann Edwin , Kosloske Ashley M. , Gibson Alice A. , Li Lie , Zeeh Dorothea , Schlatter Eberhard , Janke Laura J. , Ciarimboli Giuliano , Sparreboom Alex
Published: April 2023

PDF file - 181K
Supplementary Figure 1 from Cisplatin-Induced Renal Injury Is Independently Mediated by OCT2 and p53
Authors: Sprowl Jason A. , Lancaster Cynthia S. , Pabla Navjotsingh , Hermann Edwin , Kosloske Ashley M. , Gibson Alice A. , Li Lie , Zeeh Dorothea , Schlatter Eberhard , Janke Laura J. , Ciarimboli Giuliano , Sparreboom Alex
Published: April 2023

PDF file - 117K, Pathways implicated in cisplatin-induced renal toxicity.
Supplemental Figure 6. from NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem–Like Cells in Adenoid Cystic Carcinoma
Authors: Panaccione Alex , Chang Michael T. , Carbone Beatrice E. , Guo Yan , Moskaluk Christopher A. , Virk Renu K. , Chiriboga Luis , Prasad Manju L. , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Ivanov Sergey V.
Published: April 2023

DAPT selectively increases cell death in CD133+ Accx11 cells as shown by PE-annexin and 7-AAD double staining. DMSO treatment serves as a control.
Supplemental figure legends from Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations
Authors: Bucheit Amanda D. , Chen Guo , Siroy Alan , Tetzlaff Michael , Broaddus Russell , Milton Denai , Fox Patricia , Bassett Roland , Hwu Patrick , Gershenwald Jeffrey E. , Lazar Alexander J. , Davies Michael A.
Published: April 2023

Supplemental figure legends. Legends for supplemental figures
Supplemental Figure 4. from NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem–Like Cells in Adenoid Cystic Carcinoma
Authors: Panaccione Alex , Chang Michael T. , Carbone Beatrice E. , Guo Yan , Moskaluk Christopher A. , Virk Renu K. , Chiriboga Luis , Prasad Manju L. , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Ivanov Sergey V.
Published: April 2023

Isolation and characterization of CD133 fractions from ACC xenografts. (A) Variation in the percentage of CD133+ cells across ACC xenografts. (B) qRT-PCR analysis of CD133 expression confirms adequate separation of CD133+ and CD133- cells isolated from ACC xenografts. (C-E) Selectivity of SOX10, NOTCH1, and FABP7 to CD133+ cells isolated directly from ACC xenografts as confirmed by qRT-PCR. (F, G) Selectivity of JAG1 and NR2F1 to CD133- cells isolated directly from ACC xenografts as confirmed by qRT-PCR.
Supplementary Figure Legend from CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Authors: DeMichele Angela , Clark Amy S. , Tan Kay See , Heitjan Daniel F. , Gramlich Kristi , Gallagher Maryann , Lal Priti , Feldman Michael , Zhang Paul , Colameco Christopher , Lewis David , Langer Melissa , Goodman Noah , Domchek Susan , Gogineni Keerthi , Rosen Mark , Fox Kevin , O'Dwyer Peter
Published: April 2023

Legend for Supplementary Figures 1-2
Supplemental Figure 3. from NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem–Like Cells in Adenoid Cystic Carcinoma
Authors: Panaccione Alex , Chang Michael T. , Carbone Beatrice E. , Guo Yan , Moskaluk Christopher A. , Virk Renu K. , Chiriboga Luis , Prasad Manju L. , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Ivanov Sergey V.
Published: April 2023

FACS analysis of Accx11 cells stained with PE-conjugated CD133 antibody. Expression analysis of Accx19 cultured cells by qRT-PCR demonstrates enrichment of CD133+ markers (A) and CD133- markers (B), similar to the pattern seen in Accx11 cells. Expression is normalized to β-actin and error bars are standard error representative of at least two independent experiments.
Supplementary Tables 1-4, Figure 1 from The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL)
Authors: Litvinov Ivan V. , Netchiporouk Elena , Cordeiro Brendan , Doré Marc-André , Moreau Linda , Pehr Kevin , Gilbert Martin , Zhou Youwen , Sasseville Denis , Kupper Thomas S.
Published: April 2023

Supplementary Tables 1-4, Figure 1. Supplementary Table 1. Primers used for RT-PCR experiments. Supplementary Table 2. Detailed description of the 52 genes that fit into the three signature pattern expression model and their putative functions in CTCL and other malignancies. Supplementary Table 3. Multivariate analysis of patient characteristics that are associated with clinical disease progression. Supplementary Table 4. Description of genes that are able to distinguish CTCL from benign dermatoses and their putative roles in CTCL and other malignancies. Supplementary Figure 1. A. WIF1 (Wnt Inhibitory Factor 1) gene is expressed in normal skin and CTCL lesional skin in a subset of patients. B. Correlation of WIF1 expression in CTCL patients with disease progression. Kaplan-Meier analysis documents that loss of WIF1 expression is associated with poor CTCL disease progression (left panel, p=0.002). Disease progression is defined as a progression to a higher clinical stage and/or death. Loss of WIF1 is also associated with poor cancer specific survival (right panel, p=0.012).
Supplemental figure legends S1-S19 from ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy
Authors: Chen Zheng , Teo Albert E. , McCarty Nami
Published: April 2023

Supplemental Figure Legends
Supplemental Table 2 from Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling
Authors: Romick-Rosendale Lindsey E. , Hoskins Elizabeth E. , Privette Vinnedge Lisa M. , Foglesong Grant D. , Brusadelli Marion G. , Potter S. Steven , Komurov Kakajan , Brugmann Samantha A. , Lambert Paul F. , Kimple Randall J. , Virts Elizabeth L. , Hanenberg Helmut , Gillison Maura L. , Wells Susanne I.
Published: April 2023

RNA sequencing data. Gene ontologies and the associated genes based on biological processes with the most significance based on p-values and corrected q-values.
Supplementary Figure 3 from Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Authors: Dai Min , Yip Yuen Yee , Hellstrom Ingegerd , Hellstrom Karl Erik
Published: April 2023

Depleted of CD19 cells by the 4 mAb combination.
Supplemental Table 1 from Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling
Authors: Romick-Rosendale Lindsey E. , Hoskins Elizabeth E. , Privette Vinnedge Lisa M. , Foglesong Grant D. , Brusadelli Marion G. , Potter S. Steven , Komurov Kakajan , Brugmann Samantha A. , Lambert Paul F. , Kimple Randall J. , Virts Elizabeth L. , Hanenberg Helmut , Gillison Maura L. , Wells Susanne I.
Published: April 2023

RNA sequencing data.
Supplemental Figure 4 from Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling
Authors: Romick-Rosendale Lindsey E. , Hoskins Elizabeth E. , Privette Vinnedge Lisa M. , Foglesong Grant D. , Brusadelli Marion G. , Potter S. Steven , Komurov Kakajan , Brugmann Samantha A. , Lambert Paul F. , Kimple Randall J. , Virts Elizabeth L. , Hanenberg Helmut , Gillison Maura L. , Wells Susanne I.
Published: April 2023

DNA-PK and Rac1 activity promote UM-SCC47 cell invasion.
Supplemental Figure 1 from HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx
Authors: Dahlstrom Kristina R. , Anderson Karen S. , Cheng Julia N. , Chowell Diego , Li Guojun , Posner Marshall , Sturgis Erich M.
Published: April 2023

Limit of Detection of HPV serologic assay. Serial dilutions were performed with increasing dilution of a serum positive for E7-GST Abs using the magnetic bead RAPID ELISA assay. Error bars are calculated using 1 SD of the mean.
Supplemental Results from A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
Authors: Gupta Shilpa , Argilés Guillem , Munster Pamela N. , Hollebecque Antoine , Dajani Olav , Cheng Jonathan D. , Wang Ruixue , Swift Ann , Tosolini Alessandra , Piha-Paul Sarina A.
Published: April 2023

Supplemental Results. Using a custom designed Affymetrix microarray, we describe a RAS pathway activation signature consisting of 147 gene transcripts identified by combining data from fresh-frozen tissue samples, cell lines, and the literature.
supplemental figures from Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma
Authors: Fontana Francesca , Ge Xia , Su Xinming , Hathi Deep , Xiang Jingyu , Cenci Simone , Civitelli Roberto , Shoghi Kooresh I. , Akers Walter J. , D'avignon Andre , Weilbaecher Katherine N. , Shokeen Monica
Published: April 2023

Supplementary Figure 1 A) 1H NMR spectra (CPMG) of conditioned medium from human U266 MMC cells upon incubation for 0 (bottom), 4 (middle) or 18 (top) hours with 10 mM acetate. t-But= t-butanol standard, Lac= lactate (1.31-1.32 ppm), A= alanine (3-position at 1.5 ppm), Acetate=acetate (1.91 ppm), Glu=glutamate (2.34-2.38 ppm), Glc = glucose (5.24 ppm). Supplementary Figure 2 A) 1H NMR analysis in CPMG (top) and gHSQC (bottom) sequences of intracellular extracts from U266 upon 8h incubation with 13C-Acetate 10mM with CHC 2.5 mM (left) or vehicle (DMSO, right). Arrows: acetate peak (1.91 ppm) in HSQC sequences (13C-labeled). Supplementary Figure 3 A) Optical (GFP) and 11C-Acetate PET/CT in KaLwRij mice with bi-lateral flank subcutaneous 5TGM1 tumors (T1 and T2): imaging (i) and TAC (ii) of tumors vs. muscle, p<0.01 by ANOVA. Supplementary Figure 4 A) Percentage of dead cells (7-AAD positive) in tissue homogenates from subcutaneous MM tumors of bortezomib-treated mice relative to vehicle-treated tumors or non-tumor-bearing tissues of both treatment groups (ANOVA, Tuckey's multiple comparison test, ** p<0.01)
Supplemental figure legend from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
Authors: Wang Kai , Russell Jeffery S. , McDermott Jessica D. , Elvin Julia A. , Khaira Depinder , Johnson Adrienne , Jennings Timothy A. , Ali Siraj M. , Murray Molly , Marshall Carrie , Oldham Dwight S. , Washburn Donna , Wong Stuart J. , Chmielecki Juliann , Yelensky Roman , Lipson Doron , Miller Vincent A. , Stephens Philip J. , Serracino Hilary S. , Ross Jeffrey S. , Bowles Daniel W.
Published: April 2023

This is the legend for the supplemental figure
Supplemental Text from Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma
Authors: Fontana Francesca , Ge Xia , Su Xinming , Hathi Deep , Xiang Jingyu , Cenci Simone , Civitelli Roberto , Shoghi Kooresh I. , Akers Walter J. , D'avignon Andre , Weilbaecher Katherine N. , Shokeen Monica
Published: April 2023

NMR measurement: Sample preparation and analysis
Supplemental figure 1 from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
Authors: Wang Kai , Russell Jeffery S. , McDermott Jessica D. , Elvin Julia A. , Khaira Depinder , Johnson Adrienne , Jennings Timothy A. , Ali Siraj M. , Murray Molly , Marshall Carrie , Oldham Dwight S. , Washburn Donna , Wong Stuart J. , Chmielecki Juliann , Yelensky Roman , Lipson Doron , Miller Vincent A. , Stephens Philip J. , Serracino Hilary S. , Ross Jeffrey S. , Bowles Daniel W.
Published: April 2023

Photomicrographs of two ETV6-NTRK3 fusion cases.
Supplemental Figure 1 from Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
Authors: DuBois Steven G. , Groshen Susan , Park Julie R. , Haas-Kogan Daphne A. , Yang Xiaodong , Geier Ethan , Chen Eugene , Giacomini Kathy , Weiss Brian , Cohn Susan L. , Granger M. Meaghan , Yanik Gregory A. , Hawkins Randall , Courtier Jesse , Jackson Hollie , Goodarzian Fariba , Shimada Hiroyuki , Czarnecki Scarlett , Tsao-Wei Denice , Villablanca Judith G. , Marachelian Araz , Matthay Katherine K.
Published: April 2023

Supplemental Figure 1. PCR cycle count for NET mRNA expression in peripheral blood mononuclear cells from 7 patients obtained on Day 1 and/or 3 of protocol therapy.
Supplementary Figure Legends from Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
Authors: Hu Wenyue , Sung Tae , Jessen Bart A. , Thibault Stephane , Finkelstein Martin B. , Khan Nasir K. , Sacaan Aida I.
Published: April 2023

Supplementary figure legends
Supplemental Tables and Figures from Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
Authors: Hu Wenyue , Sung Tae , Jessen Bart A. , Thibault Stephane , Finkelstein Martin B. , Khan Nasir K. , Sacaan Aida I.
Published: April 2023

Supplementary Table S1-2. Table S1 - Clinical exposure for palbociclib, fulvestrant and chemotherapeutic agents used in this study. Table S2 - Cell cycle analysis in human bone marrow mononuclear cells treated with palbociclib for 4 days. Supplementary Figure S1-4. Figure S1 - Microscopic images of bone marrow sternum taken from A) a female dog treated with vehicle control and B) a female dog treated with palbociclib at 3 mg/kg/day for 274 days. Figure S2 - Assessment of lineage-specific effects of palbociclib treatment in human bone marrow CD34+ hematopoietic stem cells. Figure S3 - Assessment of effect of palbociclib treatment in human peripheral blood mononuclear cells (hPBMCs). Figure S4 - Assessment of relative estrogen receptor alpha (ERα) and retinoblastoma 1 (Rb1) expression in hBMNCs and MCF-7 cells using qRT-PCR.
Supplementary Figure S3 from Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
Authors: O'Connor James P.B. , Rose Chris J. , Waterton John C. , Carano Richard A.D. , Parker Geoff J.M. , Jackson Alan
Published: April 2023

Supplementary Figure S3. Feature analysis
Supplementary Figure S3 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
Authors: Tsai Harrison , Morais Carlos L. , Alshalalfa Mohammed , Tan Hsueh-Li , Haddad Zaid , Hicks Jessica , Gupta Nilesh , Epstein Jonathan I. , Netto George J. , Isaacs William B. , Luo Jun , Mehra Rohit , Vessella Robert L. , Karnes R. Jeffrey , Schaeffer Edward M. , Davicioni Elai , De Marzo Angelo M. , Lotan Tamara L.
Published: April 2023

Supplementary Figure S3: Short-term and neo-adjuvant androgen deprivation therapy (ADT) has not exhibited direct effects on CCND1, CDKN2A, or RB1 in past gene expression studies of prostatic adenocarcinomas.
Supplementary Figure S2 from Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
Authors: O'Connor James P.B. , Rose Chris J. , Waterton John C. , Carano Richard A.D. , Parker Geoff J.M. , Jackson Alan
Published: April 2023

Supplementary Figure S2. Number of histogram analyses of tumor imaging data between January 1990 and October 2014.
Supplementary Figure S1 from Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
Authors: O'Connor James P.B. , Rose Chris J. , Waterton John C. , Carano Richard A.D. , Parker Geoff J.M. , Jackson Alan
Published: April 2023

Supplementary Figure S1: Histogram analysis
Supplementary Figure S1 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
Authors: Tsai Harrison , Morais Carlos L. , Alshalalfa Mohammed , Tan Hsueh-Li , Haddad Zaid , Hicks Jessica , Gupta Nilesh , Epstein Jonathan I. , Netto George J. , Isaacs William B. , Luo Jun , Mehra Rohit , Vessella Robert L. , Karnes R. Jeffrey , Schaeffer Edward M. , Davicioni Elai , De Marzo Angelo M. , Lotan Tamara L.
Published: April 2023

Supplementary Figure S1: The ratio of CDKN2A/CCND1 reflects Rb functional and genetic status and distinguishes small cell carcinoma from prostatic adenocarcinoma in publicly available data from patient derived xenografts (PDX).
Supplementary Figure 4 from Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Authors: Tucker Douglass W. , Getchell Christopher R. , McCarthy Eric T. , Ohman Anders W. , Sasamoto Naoko , Xu Shuyun , Ko Joo Yeon , Gupta Mamta , Shafrir Amy , Medina Jamie E. , Lee Jonathan J. , MacDonald Lauren A. , Malik Ammara , Hasselblatt Kathleen T , Li Wenjing , Zhang Hong , Kaplan Samuel J. , Murphy George F. , Hirsch Michelle S. , Liu Joyce F. , Matulonis Ursula A. , Terry Kathryn L. , Lian Christine G. , Dinulescu Daniela M.
Published: April 2023

A2780 immunoblot and IC50 one week after 5-aza treatments, additional cell line IC50's
Supplemental Table S1 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Authors: Boi Michela , Gaudio Eugenio , Bonetti Paola , Kwee Ivo , Bernasconi Elena , Tarantelli Chiara , Rinaldi Andrea , Testoni Monica , Cascione Luciano , Ponzoni Maurilio , Mensah Afua Adjeiwaa , Stathis Anastasios , Stussi Georg , Riveiro María Eugenia , Herait Patrice , Inghirami Giorgio , Cvitkovic Esteban , Zucca Emanuele , Bertoni Francesco
Published: April 2023

Supplemental Table S1: Cell lines and growth medium.
Supplemental Figures S7 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Authors: Boi Michela , Gaudio Eugenio , Bonetti Paola , Kwee Ivo , Bernasconi Elena , Tarantelli Chiara , Rinaldi Andrea , Testoni Monica , Cascione Luciano , Ponzoni Maurilio , Mensah Afua Adjeiwaa , Stathis Anastasios , Stussi Georg , Riveiro María Eugenia , Herait Patrice , Inghirami Giorgio , Cvitkovic Esteban , Zucca Emanuele , Bertoni Francesco
Published: April 2023

Supplemental Figures S7. Supplemental Figures S7. Effects of JQ1 and OTX015 on BRD4 binding to MYD88 promoter region in DLBCL cell lines.
Supplemental Figures S6 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Authors: Boi Michela , Gaudio Eugenio , Bonetti Paola , Kwee Ivo , Bernasconi Elena , Tarantelli Chiara , Rinaldi Andrea , Testoni Monica , Cascione Luciano , Ponzoni Maurilio , Mensah Afua Adjeiwaa , Stathis Anastasios , Stussi Georg , Riveiro María Eugenia , Herait Patrice , Inghirami Giorgio , Cvitkovic Esteban , Zucca Emanuele , Bertoni Francesco
Published: April 2023

Supplemental Figures S6. Supplemental Figures S6: OTX015 effects on the production of IL-4 and IL-10 in DLBCL cell lines.
supplemental tables from Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Authors: Guo Yelei , Feng Kaichao , Liu Yang , Wu Zhiqiang , Dai Hanren , Yang Qingming , Wang Yao , Jia Hejin , Han Weidong
Published: April 2023

Supplemental Table 1. Immunohistochemistry score of EGFR expression Supplemental Table 2. Level of cytokines, C-reactive protein (CRP) and transgene copies after the CART-RGFR cell infusion
Supplemental Figures S1-2 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Authors: Boi Michela , Gaudio Eugenio , Bonetti Paola , Kwee Ivo , Bernasconi Elena , Tarantelli Chiara , Rinaldi Andrea , Testoni Monica , Cascione Luciano , Ponzoni Maurilio , Mensah Afua Adjeiwaa , Stathis Anastasios , Stussi Georg , Riveiro María Eugenia , Herait Patrice , Inghirami Giorgio , Cvitkovic Esteban , Zucca Emanuele , Bertoni Francesco
Published: April 2023

Supplemental Figures S1-2. Supplemental Figures S1: effects of OTX015 on cell cycle and cell growth in DLBCL cell lines. Supplemental Figures S2: effects of OTX015 on apoptosis in DLBCL cell lines.
supplemental methods from Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Authors: Guo Yelei , Feng Kaichao , Liu Yang , Wu Zhiqiang , Dai Hanren , Yang Qingming , Wang Yao , Jia Hejin , Han Weidong
Published: April 2023

supplemental methods
Supplemental Figure S2 from Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo
Authors: Kimbrough Charles W. , Khanal Anil , Zeiderman Matthew , Khanal Bigya R. , Burton Neal C. , McMasters Kelly M. , Vickers Selwyn M. , Grizzle William E. , McNally Lacey R.
Published: April 2023

Supplemental Figure S2: As the K7-750 probe did not bind to pancreas tumors, deoxy-hemoglobin signal was utilized to denote the location of the pancreas tumors. Orthogonal views of deoxy-hemoglobin signal indicate the location of the pancreatic tumor bed in both S2VP10 and S2013 xenografts. (A) Orthogonal view of deoxy-hemoglobin signal indicating the S2VP10 tumor within the mouse. Mouse shown is the same mouse shown as injected with V7-750 probe in Figure 3. MSOT images of this mouse are also available as a movie clip (Supplement Figure S5). (B) Orthogonal view of deoxy-hemoglobin signal indicating the S2VP10 tumor within the mouse that was injected with K7-750 (mouse shown from Figure 3).
Supplementary Figure 1 from A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
Authors: Moreno Lucas , Marshall Lynley V. , Pearson Andrew D.J. , Morland Bruce , Elliott Martin , Campbell-Hewson Quentin , Makin Guy , Halford Sarah E.R. , Acton Gary , Ross Philip , Kazmi-Stokes Shamim , Lock Victoria , Rodriguez Ana , Lyons John F. , Boddy Alan V. , Griffin Melanie J. , Yule Murray , Hargrave Darren
Published: April 2023

Supplementary Figure 1. Examples of changes observed in M30/M65 profiles as a function of dosing of AT9283 in two selected patients. Pt. 58/032 from cohort 4 (14.5 mg/m2/day) and Pt. 31/030 from cohort 6 (23 mg/m2/day).
Supplemental Figure S1 from Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo
Authors: Kimbrough Charles W. , Khanal Anil , Zeiderman Matthew , Khanal Bigya R. , Burton Neal C. , McMasters Kelly M. , Vickers Selwyn M. , Grizzle William E. , McNally Lacey R.
Published: April 2023

Supplemental Figure S1: (A) Uv-Vis absorbance of K7-750 and V7-750 probes at 40 μM peptide concentration. Absorbance peak at 280 nm shows the peptide peak, while absorbance peak at 750 nm shows the dye peak. (B) Normalized absorbance of V7-750, K7-750, deoxy-hemoglobin, and oxy-hemoglobin. These spectra were utilized for spectral unmixing of images acquired using MSOT imaging.
Supplementary Figure S1 from pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27+ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma
Authors: Ruf Melanie , Mittmann Christiane , Nowicka Anna M. , Hartmann Arndt , Hermanns Thomas , Poyet Cédric , van den Broek Maries , Sulser Tullio , Moch Holger , Schraml Peter
Published: April 2023

Western blot of 786-O and A498 lysates untreated and treated with PNGase F. NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc/) predicts two N-linked glycosylation sites within the CD70 amino acid sequence. De-glycosylation reduced CD70 mainly to its native monomer of about 20 kDa.
Supplementary Figure 2 from Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer
Authors: Zhang Xin , Yang Xiaoyun , Zhang Yanli , Liu Xinfeng , Zheng Guixi , Yang Yongmei , Wang Lili , Du Lutao , Wang Chuanxin
Published: April 2023

Supplementary Figure 2. Serum CEA levels in NC, HP, IBD, Ad and CRC.
Supplementary Figure 1 from Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer
Authors: Zhang Xin , Yang Xiaoyun , Zhang Yanli , Liu Xinfeng , Zheng Guixi , Yang Yongmei , Wang Lili , Du Lutao , Wang Chuanxin
Published: April 2023

Supplementary Figure 1. Quantitative analyses of serum cell free Bmi-1 mRNA using RT-qPCR-D in NC , HP, IBD, non-advanced Ad and advanced Ad.
Supplementary Tables 1-6, Supplementary Figure Legend from Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Authors: Shah Jatin J. , Jakubowiak Andrzej J. , O'Connor Owen A. , Orlowski Robert Z. , Harvey R. Donald , Smith Mitchell R. , Lebovic Daniel , Diefenbach Catherine , Kelly Kevin , Hua Zhaowei , Berger Allison J. , Mulligan George , Faessel Hélène M. , Tirrell Stephen , Dezube Bruce J. , Lonial Sagar
Published: April 2023

Table A1. Prior therapies received (agents received by >5 patients); Table A2. Summary of pevonedistat plasma pharmacokinetic parameters on days 1 and 9 of cycle 1 on schedule A (administration on days 1, 2, 8, 9 of 21-day cycles); Table A3. Summary of pevonedistat plasma pharmacokinetic parameters on days 1 and 4 (or, alternatively, day 11) of cycle 1 on schedule B (administration on days 1, 4, 8, 11 of 21-day cycles); Table A4. Changes from baseline in gene expression levels for NAEregulated transcriptional targets on cycle 1, day 1 following pevonedistat administration at the MTDs on schedules A and B; Table A5. Patients achieving partial responses; Table A6. Patients achieving stable disease and receiving at least 5 cycles of pevonedistat.
Supplementary Figure 1 from Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Authors: Shah Jatin J. , Jakubowiak Andrzej J. , O'Connor Owen A. , Orlowski Robert Z. , Harvey R. Donald , Smith Mitchell R. , Lebovic Daniel , Diefenbach Catherine , Kelly Kevin , Hua Zhaowei , Berger Allison J. , Mulligan George , Faessel Hélène M. , Tirrell Stephen , Dezube Bruce J. , Lonial Sagar
Published: April 2023

Representative images (20 x magnification) of formalin-fixed paraffin-embedded clots prepared from bone marrow aspirates.
Supplementary data from Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
Authors: Misiewicz-Krzeminska Irena , Sarasquete María E. , Vicente-Dueñas Carolina , Krzeminski Patryk , Wiktorska Katarzyna , Corchete Luis Antonio , Quwaider Dalia , Rojas Elizabeta A. , Corral Rocío , Martín Ana A. , Escalante Fernando , Bárez Abelardo , García Juan Luis , Sánchez-García Isidro , García-Sanz Ramón , San Miguel Jesús F. , Gutiérrez Norma C.
Published: April 2023

Supplementary Tables Supplementary Table 1. Cytogenetic characteristics of MM samples Supplementary Table 2. Sequences of primers used in the study Supplementary Table 3. CCND2 mRNA FISH probes sequences Supplementary table 4. microRNAs predicted to target CCND1 or/and CCND2 Supplementary table 5. microRNAs expression in MM cell lines. Supplementary Figures Supplementary Figure 1. CCND2 mRNA level 24h after transfection of MM1S, RPMI and H929 cell lines with indicated miRNAs Supplementary Figure 2. Expression of miR-15a and miR-196b in H929 and MM1S cell lines after transfection Supplementary Figure 3. (A) Alignment of 3'RACE PCR product sequence from MM1S cell line with CCND2 mRNA (NM_001759.3). (B) Sequence of the 3'RACE PCR product withhighlighted APA signal. Supplementary Figure 4. CCND2 mRNA expression visualized with FISH probes Supplementary Figure 5. Luciferase activity in HEK923 cells cotransfected with various miRNAs, plasmid encoding GFP and plasmid containing luciferase and 3'UTR of CCND2 short isoform Supplementary Figure 6. Regulation of cyclin D2 level by CCND1/CCND3.
Supplemental Data from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Authors: Charych Deborah H. , Hoch Ute , Langowski John L. , Lee Steve R. , Addepalli Murali K. , Kirk Peter B. , Sheng Dawei , Liu Xiaofeng , Sims Paul W. , VanderVeen Laurie A. , Ali Cherie F. , Chang Thomas K. , Konakova Marina , Pena Rhoneil L. , Kanhere Rupesh S. , Kirksey Yolanda M. , Ji Chunmei , Wang Yujun , Huang Jicai , Sweeney Theresa D. , Kantak Seema S. , Doberstein Stephen K.
Published: April 2023

Supplemental Materials and Methods. ELISA study materials; NKTR-214 chemistry; Mapping of PEGylation sites; Identification of active released IL-2 conjugates; Binding affinity to IL-2 receptors; In vivo immune cell phenotyping, In vivo immune cell phenotyping; In vivo T cell antigen staining; In vivo depletion of immune cells; Hematology parameters for evaluation of immune markers in non-human primates. Supplemental Figure Legends S1-S4. Supplemental Tables S1 and S2. Table S1: Fold change of affinity to IL-2αβ and IL-2β for NKTR-214 and its released active IL-2 conjugates compared to aldesleukin; Table S2: Activation of Primary Cynomulgus Monkey and Human T Cells in Response to IL-2 and the Active Metabolite of NKTR-214
Supplementary Table 2 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Authors: Garcia Jacqueline S. , Huang Min , Medeiros Bruno C. , Mitchell Beverly S.
Published: April 2023

Patient characteristics and molecular phenotypes of primary AML samples used.
Supplementary Figure 6 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Authors: Garcia Jacqueline S. , Huang Min , Medeiros Bruno C. , Mitchell Beverly S.
Published: April 2023

Effects of combining ixazomib and Trichostatin A (TSA) (A, B, C), and of combining bortezomib and SAHA (D, E) in OCI-AML3 cells with or without depletion of NPMc+ expression.
Supplementary Figure 5 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Authors: Garcia Jacqueline S. , Huang Min , Medeiros Bruno C. , Mitchell Beverly S.
Published: April 2023

In vivo analysis of patients AML1-3 including (A) H2O2 levels, (B) WBC counts of AML3 during ixazomib treatment (arrow marks when hydrea stopped), and (C) mRNA expression (AML2).
Figure S1 from CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer
Authors: Michaels Alex D. , Newhook Timothy E. , Adair Sara J. , Morioka Sho , Goudreau Bernadette J. , Nagdas Sarbajeet , Mullen Matthew G. , Persily Jesse B. , Bullock Timothy N. J. , Slingluff Craig L. , Ravichandran Kodi S. , Parsons J. Thomas , Bauer Todd W.
Published: April 2023

Supplementary Figure S1. Macrophage depletion following clodronate treatment. Flow cytometry dot-plots of athymic nude mouse whole-liver digests at days 2, 8, and 12 following splenic injection of T608 patient-derived pancreatic ductal adenocarcinoma cells in mice treated with liposomal clodronate (n = 2 per timepoint) versus untreated mice (n = 3 per timepoint). Percentage of resident liver macrophages (F4/80highCD11blow cells) among the CD11b+ population in the liver is displayed.
Supplementary Figure 2 from SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor
Authors: Chiang Cheng-Yao , Pan Chin-Chen , Chang Hong-Yi , Lai Ming-Derg , Tzai Tzong-Shin , Tsai Yuh-Shyan , Ling Pin , Liu Hsiao-Sheng , Lee Bi-Fang , Cheng Hong-Ling , Ho Chung-Liang , Chen Shu-Hui , Chow Nan-Haw
Published: April 2023

SH3BGRL3 expression level in uroepithelial cell lines, xenografts and alternation of EMT markers by transient transfection of SH3BGRL3
Supplementary Figure 2 from Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Authors: Gainor Justin F. , Tan Daniel S.W. , De Pas Tomasso , Solomon Benjamin J. , Ahmad Aziah , Lazzari Chiara , de Marinis Filippo , Spitaleri Gianluca , Schultz Katherine , Friboulet Luc , Yeap Beow Y. , Engelman Jeffrey A. , Shaw Alice T.
Published: April 2023

Supplementary Figure 2. Overall survival (OS) for anaplastic lymphoma kinase (ALK)-positive patients with brain metastases
Supplementary Methods, Figures S1-S2, Table S1-S2 from Identification of a Variant in KDR Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib
Authors: Maitland Michael L. , Xu Chun-Fang , Cheng Yu-Ching , Kistner-Griffin Emily , Ryan Kathleen A. , Karrison Theodore G. , Das Soma , Torgerson Dara , Gamazon Eric R. , Thomeas Vasiliki , Levine Matthew R. , Wilson Paul A. , Bing Nan , Liu Yuan , Cardon Lon R. , Pandite Lini N. , O'Connell Jeffrey R. , Cox Nancy J. , Mitchell Braxton D. , Ratain Mark J. , Shuldiner Alan R.
Published: April 2023

Materials and Methods Fig. S1. Linkage disequilibrium (LD) between rs725344 and SNPs from the IBC chip within KDR in the Old Order Amish. Fig. S2. Interspecies conservation of C482 in homologous sequences. Table S1. Candidate variants within the 4MB linkage peak tested in 128 cancer patients for association with [sVEGFR2]. Table S2. Polymorphisms within KDR strongly associated with serum concentrations of sVEGFR2 in the Amish.
Supplementary Figure 4 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Authors: Zegers Catharina M.L. , Rekers Nicolle H. , Quaden Dana H.F. , Lieuwes Natasja G. , Yaromina Ala , Germeraad Wilfred T.V. , Wieten Lotte , Biessen Erik A.L. , Boon Louis , Neri Dario , Troost Esther G.C. , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary Figure 4. Cytotoxic T cells (CD8+) as a % of CD45+ cells.
Supplementary Figure 3 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Authors: Zegers Catharina M.L. , Rekers Nicolle H. , Quaden Dana H.F. , Lieuwes Natasja G. , Yaromina Ala , Germeraad Wilfred T.V. , Wieten Lotte , Biessen Erik A.L. , Boon Louis , Neri Dario , Troost Esther G.C. , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary Figure 3. FACS gating strategy (blood)
Supplementary Figures S1-S11 from Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
Authors: Arqués Oriol , Chicote Irene , Puig Isabel , Tenbaum Stephan P. , Argilés Guillem , Dienstmann Rodrigo , Fernández Natalia , Caratù Ginevra , Matito Judit , Silberschmidt Daniel , Rodon Jordi , Landolfi Stefania , Prat Aleix , Espín Eloy , Charco Ramón , Nuciforo Paolo , Vivancos Ana , Shao Wenlin , Tabernero Josep , Palmer Héctor G.
Published: April 2023

Supplementary Figures S1-S11. Figure S1. Apoptosis of CRC patient-derived cells upon treatment with API-2 or NVP-BKM120 in combination with XAV939. Figure S2. Evaluation of apoptosis in primary sphere cell cultures by immunofluorescent quantification of cleaved-CASPASE3. Figure S3. Frequent mutations in CRC do not determine the response to API2, NVP-BKM120 or NVP-TNKS656. Figure S4. NVP-TNKS656 is not toxic and reduces nuclear β-catenin in the skin and small intestine in NOD-SCID mice. Figure S5. Analyses of pharmacodynamic markers at endpoint of in vivo experiments with API2 and NVP-TNKS656. Figure S6. Nuclear FOXO3A content is preserved in PDX and primary sphere cultures. Figure S7. Nuclear FOXO3A in paired primary tumors and liver metastases. Figure S8. Immunohistochemical staining of β-catenin in CRC tumors. Figure S9. β-catenin in single-agent treatments, relevant mutations, TNM stage or tumor site do not associate with a differential response to PI3K/AKT/mTOR inhibitors. Figure S10. Gene expression clustering and mutational status of baseline tumor samples from patients treated with PI3K/AKT/mTOR inhibitors. Figure S11. Molecular prescreening scheme to select CRC patients eligible for the treatment with PI3K/AKT and/or Wnt/β-catenin inhibitory drugs.
Perez-Chacon et al=SUPPLEMENTARY INFORMATION from Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances
Authors: Perez-Chacon Gema , Martinez-Laperche Carolina , Rebolleda Nerea , Somovilla-Crespo Beatriz , Muñoz-Calleja Cecilia , Buño Ismael , Zapata Juan M.
Published: April 2023

Supplementary Table 1. Statistical analysis of the effect of the combinatory I3C/F-ara-A treatment versus single I3C or F-ara-A treatments. Supplementary Table 2. Combination index (CI) for effective dose (ED) 50, 75 and 90 for I3C combined with F-ara-A, vincristine or chlorambucil and dose reduction index (DRI) for these drugs in the combined treatment with I3C. Supplementary Figure S1. I3C is highly cytotoxic to CLL cells while having reduced cytotoxicity against PBMCs from healthy donors. Supplementary Figure S2. I3C and F-ara-A show strong synergy against CLL cells. Supplementary Figure S3. I3C cytotoxicity and synergy with F-ara-A is fully functional in the presence of human serum. Supplementary Figure S4. Effect of I3C, F-ara-A and the I3C/F-ara-A combination treatment on the expression of proteins involved in the control of apoptosis. Supplementary Figure S5. A. Effect of I3C, F-ara-A and the combined F-ara-A/I3C treatment on mitochondrial depolarization (Î”Î¨m). B. Effect of I3C, F-ara-A and the combined F-ara-A/I3C treatment on reactive oxygen species (ROS) production. Supplementary Figure S6. I3C has reduced toxicity in T cells from CLL patients compared to CLL cells.
Summary of in vivo studies from Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts
Authors: Bieniasz Magdalena , Radhakrishnan Parvathi , Faham Najme , De La O Jean-Paul , Welm Alana L.
Published: April 2023

Summary of in vivo studies
Supplemental Methods from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Authors: Andreeff Michael , Kelly Kevin R. , Yee Karen , Assouline Sarit , Strair Roger , Popplewell Leslie , Bowen David , Martinelli Giovanni , Drummond Mark W. , Vyas Paresh , Kirschbaum Mark , Iyer Swaminathan Padmanabhan , Ruvolo Vivian , González Graciela M. Nogueras , Huang Xuelin , Chen Gong , Graves Bradford , Blotner Steven , Bridge Peter , Jukofsky Lori , Middleton Steve , Reckner Monica , Rueger Ruediger , Zhi Jianguo , Nichols Gwen , Kojima Kensuke
Published: April 2023

The following information describes additional study design criteria and safety considerations used in the phase 1 clinical trial of RG7112 in patients with hematological malignancies
Supplemental Figures 1 and 2 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Authors: Andreeff Michael , Kelly Kevin R. , Yee Karen , Assouline Sarit , Strair Roger , Popplewell Leslie , Bowen David , Martinelli Giovanni , Drummond Mark W. , Vyas Paresh , Kirschbaum Mark , Iyer Swaminathan Padmanabhan , Ruvolo Vivian , González Graciela M. Nogueras , Huang Xuelin , Chen Gong , Graves Bradford , Blotner Steven , Bridge Peter , Jukofsky Lori , Middleton Steve , Reckner Monica , Rueger Ruediger , Zhi Jianguo , Nichols Gwen , Kojima Kensuke
Published: April 2023

Supplementary Fig. 1. Day 10 dose-mean PK profiles in patients with leukemia; Supplementary Figure 2. RG7112 induces p53-mediated apoptosis in circulating lymphoma cells from a patient with SLL/CLL (810 mg to 1500 mg BID)
Supplementary Materials and Methods from DNMT1–MicroRNA126 Epigenetic Circuit Contributes to Esophageal Squamous Cell Carcinoma Growth via ADAM9–EGFR–AKT Signaling
Authors: Liu Ronghua , Gu Jie , Jiang Pei , Zheng Yijie , Liu Xiaoming , Jiang Xuechao , Huang Enyu , Xiong Shudao , Xu Fengkai , Liu Guangwei , Ge Di , Chu Yiwei
Published: April 2023

This file contained the supplementary materials and methods including RNA extraction and quantitative real-time PCR, miRNA overexpression and RNA interference (RNAi), Cell proliferation and migration assays, Immunohistochemistry (IHC) and Western blotting, EGFR inhibitor (AG1478) and 5-aza-2'-deoxycytidine (5-aza-dC) treatments, ISH scoring, DNA methylation analysis, Target prediction, 3'-UTR vector preparation, and luciferase reporter assay, Tumor xenograft in nude mice, mRNA sequencing. As well as, legends of the six supplementary figures were included in this file.
Data Supplement from Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma
Authors: Brown Noah A. , Rolland Delphine , McHugh Jonathan B. , Weigelin Helmut C. , Zhao Lili , Lim Megan S. , Elenitoba-Johnson Kojo S.J. , Betz Bryan L.
Published: April 2023

Supplemental Figure S1. Sequence electropherograms and histopathology from representative cases with CTNNB1, PIK3CA, NRAS, FGFR2, SMARCB1, HRAS and SMO mutations.
Supplementary Table (S6) from HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis
Authors: Abdel-Fatah Tarek M.A. , McArdle Stephanie E.B. , Agarwal Devika , Moseley Paul M. , Green Andrew R. , Ball Graham R. , Pockley A. Graham , Ellis Ian O. , Rees Robert C. , Chan Stephen Y.T.
Published: April 2023

Supplementary Table (S6). A list of the top 100 genes and pathways involved in the HAGE network. Created through the application of a non-linear, artificial neural network (ANN) modelling based, data mining approach applied to the TNBC cohort trial dataset (NCT00455533).
Supplementary Figure S3 from DNMT1–MicroRNA126 Epigenetic Circuit Contributes to Esophageal Squamous Cell Carcinoma Growth via ADAM9–EGFR–AKT Signaling
Authors: Liu Ronghua , Gu Jie , Jiang Pei , Zheng Yijie , Liu Xiaoming , Jiang Xuechao , Huang Enyu , Xiong Shudao , Xu Fengkai , Liu Guangwei , Ge Di , Chu Yiwei
Published: April 2023

Supplementary Figure S3. Suppressive effect of miR-126 on ESCC cell migration and growth.
Supplementary Table (S3) from HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis
Authors: Abdel-Fatah Tarek M.A. , McArdle Stephanie E.B. , Agarwal Devika , Moseley Paul M. , Green Andrew R. , Ball Graham R. , Pockley A. Graham , Ellis Ian O. , Rees Robert C. , Chan Stephen Y.T.
Published: April 2023

Supplementary Table (S3). Clinico-pathological characteristics of primary locally advanced triple negative breast cancer cohort (PLA-TNBC; n=110)
Supplemental Table 2 from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models
Authors: Schuller Alwin G. , Barry Evan R. , Jones Rhys D.O. , Henry Ryan E. , Frigault Melanie M. , Beran Garry , Linsenmayer David , Hattersley Maureen , Smith Aaron , Wilson Joanne , Cairo Stefano , Déas Olivier , Nicolle Delphine , Adam Ammar , Zinda Michael , Reimer Corinne , Fawell Stephen E. , Clark Edwin A. , D'Cruz Celina M.
Published: April 2023

Supplemental Table 2. Mutations in RCC-43b and RCC-47
Supplemental Table 1 from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models
Authors: Schuller Alwin G. , Barry Evan R. , Jones Rhys D.O. , Henry Ryan E. , Frigault Melanie M. , Beran Garry , Linsenmayer David , Hattersley Maureen , Smith Aaron , Wilson Joanne , Cairo Stefano , Déas Olivier , Nicolle Delphine , Adam Ammar , Zinda Michael , Reimer Corinne , Fawell Stephen E. , Clark Edwin A. , D'Cruz Celina M.
Published: April 2023

Supplemental Table 1. Genes with copy number gain in RCC-43b and RCC-47
Supplementary Table 3 from Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer
Authors: Sanz-Pamplona Rebeca , Lopez-Doriga Adriana , Paré-Brunet Laia , Lázaro Kira , Bellido Fernando , Alonso M. Henar , Aussó Susanna , Guinó Elisabet , Beltrán Sergi , Castro-Giner Francesc , Gut Marta , Sanjuan Xavier , Closa Adria , Cordero David , Morón-Duran Francisco D. , Soriano Antonio , Salazar Ramón , Valle Laura , Moreno Victor
Published: April 2023

List of all SNVs found
Supplementary Table 1 from Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Authors: Tarlock Katherine , Alonzo Todd A. , Gerbing Robert B. , Raimondi Susana C. , Hirsch Betsy A. , Sung Lillian , Pollard Jessica A. , Aplenc Richard , Loken Michael R. , Gamis Alan S. , Meshinchi Soheil
Published: April 2023

Multivariable Cox regression analysis for FLT3/ITD patients treated on GO and No-GO cohorts.